Wendy Selig

503 total citations
16 papers, 289 citations indexed

About

Wendy Selig is a scholar working on Cancer Research, Oncology and Economics and Econometrics. According to data from OpenAlex, Wendy Selig has authored 16 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cancer Research, 4 papers in Oncology and 4 papers in Economics and Econometrics. Recurrent topics in Wendy Selig's work include Cancer Genomics and Diagnostics (5 papers), Pharmaceutical industry and healthcare (3 papers) and Ethics in Clinical Research (3 papers). Wendy Selig is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Pharmaceutical industry and healthcare (3 papers) and Ethics in Clinical Research (3 papers). Wendy Selig collaborates with scholars based in United States, Canada and United Kingdom. Wendy Selig's co-authors include Matthew Harker, Bray Patrick‐Lake, Jamie Roberts, Sharon Hesterlee, Sophia K. Smith, Richard C. Klein, Amy P. Abernethy, Michael B. Atkins, Jonathan D. Campbell and James D. Chambers and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and Journal of Thoracic Oncology.

In The Last Decade

Wendy Selig

16 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wendy Selig United States 9 95 85 69 48 44 16 289
Donna A. Messner United States 11 40 0.4× 102 1.2× 81 1.2× 69 1.4× 36 0.8× 23 327
John J. Ko United States 11 31 0.3× 102 1.2× 50 0.7× 54 1.1× 22 0.5× 23 443
Leigh Boehmer United States 9 96 1.0× 24 0.3× 34 0.5× 53 1.1× 16 0.4× 42 253
Lisel Koepl United States 11 156 1.6× 48 0.6× 24 0.3× 37 0.8× 13 0.3× 12 325
Cheryl Marriott United Kingdom 3 55 0.6× 41 0.5× 40 0.6× 97 2.0× 33 0.8× 5 264
Leeza Osipenko United Kingdom 9 27 0.3× 115 1.4× 34 0.5× 22 0.5× 23 0.5× 22 317
Emelie Andersson Sweden 11 130 1.4× 78 0.9× 41 0.6× 38 0.8× 23 0.5× 27 442
Iyar Mazar United States 9 93 1.0× 44 0.5× 15 0.2× 23 0.5× 12 0.3× 20 313
Carole Longson United Kingdom 10 28 0.3× 138 1.6× 43 0.6× 23 0.5× 26 0.6× 22 265
Sreeram V Ramagopalan United Kingdom 8 72 0.8× 56 0.7× 15 0.2× 26 0.5× 46 1.0× 25 273

Countries citing papers authored by Wendy Selig

Since Specialization
Citations

This map shows the geographic impact of Wendy Selig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Selig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Selig more than expected).

Fields of papers citing papers by Wendy Selig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Selig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Selig. The network helps show where Wendy Selig may publish in the future.

Co-authorship network of co-authors of Wendy Selig

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Selig. A scholar is included among the top collaborators of Wendy Selig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Selig. Wendy Selig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Dave, Kuldip D., Björn Oskarsson, Terry Heiman‐Patterson, et al.. (2024). Contributions of neurologists to diagnostic timelines of ALS and thinkALS as an early referral instrument for clinicians. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 26(3-4). 215–224. 3 indexed citations
2.
Zhang, Tian, Patrick M. Forde, Ryan J. Sullivan, et al.. (2023). Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for ImmunoTherapy of Cancer. 11(5). e006555–e006555. 12 indexed citations
3.
Selig, Wendy, Brett Hauber, Shelby D. Reed, et al.. (2022). Leveraging Patient Preference Information in Medical Device Clinical Trial Design. Therapeutic Innovation & Regulatory Science. 57(1). 152–159. 4 indexed citations
4.
Gerber, David E., Harpreet Singh, Erin Larkins, et al.. (2022). A New Approach to Simplifying and Harmonizing Cancer Clinical Trials—Standardizing Eligibility Criteria. JAMA Oncology. 8(9). 1333–1333. 8 indexed citations
5.
Garcia, José M., Richard F. Dunne, Lisa Martin, et al.. (2022). Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. Journal of Cachexia Sarcopenia and Muscle. 13(2). 1418–1425. 21 indexed citations
6.
Forde, Patrick M., P. Bonomi, Alice T. Shaw, et al.. (2020). Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clinical Lung Cancer. 21(4). 295–307. 10 indexed citations
7.
Bonomi, P., Meredith K. Chuk, Alexander I. Spira, et al.. (2020). Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer. Therapeutic Innovation & Regulatory Science. 54(5). 1208–1214. 2 indexed citations
8.
Kaufman, Howard L., Michael B. Atkins, Prasun Subedi, et al.. (2019). The promise of Immuno-oncology: implications for defining the value of cancer treatment. Journal for ImmunoTherapy of Cancer. 7(1). 129–129. 75 indexed citations
9.
Bonomi, Philip, Gideon M. Blumenthal, Andrea Stern Ferris, et al.. (2018). Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology. 13(6). 748–751. 10 indexed citations
10.
Roy, Upal, Bellinda L. King‐Kallimanis, Paul G. Kluetz, Wendy Selig, & Andrea Ferris. (2018). Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials. Journal of Thoracic Oncology. 13(12). 1815–1817. 6 indexed citations
11.
Selig, Wendy, et al.. (2018). Incorporating Patient Advocates in Oncology Clinical Development: Lessons Learned From a Novel Pilot Program. Therapeutic Innovation & Regulatory Science. 53(3). 349–353. 6 indexed citations
12.
Bloom, Diane, Matthew Harker, Sharon Hesterlee, et al.. (2017). The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials. Therapeutic Innovation & Regulatory Science. 52(2). 206–213. 36 indexed citations
13.
Smith, Sophia K., Wendy Selig, Matthew Harker, et al.. (2015). Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. PLoS ONE. 10(10). e0140232–e0140232. 60 indexed citations
14.
Horning, Sandra J., Daniel A. Haber, Wendy Selig, et al.. (2013). Developing Standards for Breakthrough Therapy Designation in Oncology. Clinical Cancer Research. 19(16). 4297–4304. 24 indexed citations
15.
Hjerpe, Evan E., Wendy Selig, Dana Coelho, et al.. (2013). Breaking barriers, Building bridges: Collaborative forest landscape restoration handbook. 6 indexed citations
16.
Selig, Wendy, et al.. (2005). Examining Advocacy and Comprehensive Cancer Control. Cancer Causes & Control. 16(S1). 61–68. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna A. Messner Breakdown of academic impact, for papers by John J. Ko Breakdown of academic impact, for papers by Leigh Boehmer Breakdown of academic impact, for papers by Lisel Koepl Breakdown of academic impact, for papers by Cheryl Marriott Breakdown of academic impact, for papers by Leeza Osipenko Breakdown of academic impact, for papers by Emelie Andersson Breakdown of academic impact, for papers by Iyar Mazar Breakdown of academic impact, for papers by Carole Longson Breakdown of academic impact, for papers by Sreeram V Ramagopalan
Rankless by CCL
2026